ProNAi Therapeutics
A clinical-stage oncology company developing DNA interference (DNAi) based cancer therapies.
About
Technology stack
detected 2026-05-23No comments yet. Be the first to share your take.
What does ProNAi Therapeutics do?
ProNAi Therapeutics is a clinical-stage oncology company focused on developing and commercializing novel cancer therapies. Their proprietary DNA interference (DNAi) technology platform targets specific genes within cancer cells to inhibit proliferation and induce cell death. Their lead candidate, PNT2258, targets the BCL2 gene.
How much funding has ProNAi Therapeutics raised?
ProNAi Therapeutics has raised a total of $116M in funding. The most recent round on record is Series D.
When was ProNAi Therapeutics founded?
ProNAi Therapeutics was founded in 2004.
What industry does ProNAi Therapeutics operate in?
ProNAi Therapeutics operates in Biotech, Drug Discovery, Clinical Trials, Oncology, Phage Therapy, DNAi Technology.
What is ProNAi Therapeutics's current status?
ProNAi Therapeutics's current operating status is: Inactive.